ERBB2 and neoplasm: The increase in immune signatures, especially in CD8-positive T-cells, that we observed after 14–21 days of HER2-targeted therapy was eliminated by time of surgery, likely because the sample at surgery was largely devoid of tumor, as this result contrasts to what was observed with tumor enrichment and in situ proteomic profiling52.